New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Search
Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Breathing hope: fighting the lung disease pulmonary fibrosis
The animation and accompanying article aims to draw attention to and raise awareness about pulmonary fibrosis, a disease often misdiagnosed an overlooked.
Facing Pulmonary Fibrosis
Steve Jones talks about his experience facing his pulmonary fibrosis diagnosis.
Pulmonary Fibrosis: Early discovery makes all the difference
Video taking a deep dive into pulmonary fibrosis. Visit an underwater world that brings to life the physical change PF has on the lungs.
Pulmonary Fibrosis
Pulmonary Fibrosis
Living with pulmonary fibrosis and finding hope
From caregiver to co-founder of the European Pulmonary Fibrosis Federation, Liam Galvin shares about his experience, and the impact of ongoing research
Podcast: Journeys through pulmonary fibrosis
As we speak to the courageous pulmonary fibrosis community, we hear heart-warming stories of determination, resilience and spirit.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Our Partners Harvard
Brock Reeve, Executive Director of the Harvard Stem Cell Institute, talks about the importance of working together to tackle the challenge of fibrosis.
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
Facts about the INPULSIS™ trials
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Survodutide US FDA Breakthrough Therapy phase 3 trials MASH
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
Professor Richeldi treatment initiation
Leading pulmonologist Professor Richeldi discusses why early initiation of treatment in Idiopathic Pulmonary Fibrosis is important.
New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.